Shilpa Medicare Unit Secures Key USFDA Orphan Drug Tag

wholly-owned subsidiary, Shilpa Biologicals, in collaboration with mAbTree Biologics AG, has achieved a meaningful regulatory milestone as the U.S. Food and Drug Administration (USFDA) has granted Orphan Drug Designation to their investigational biologic aimed at treating Essential Thrombocythemia (ET) and Polycythemia Vera (PV), two rare chronic blood cancers that affect a small patient population; this orphan tag provides strategic advantages such as development incentives, potential tax credits, and eligibility for an exclusive market period upon approval, underscoring the scientific confidence in this first-in-class monoclonal antibody approach and positioning the program as a noteworthy advancement in Shilpa’s biologics pipeline focused on high unmet medical needs. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.